Immunological data from recently completed
Phase 1b trial will be presented on
April 16th
PLYMOUTH
MEETING, Pa., April 12,
2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a
biotechnology company focused on developing and commercializing DNA
medicines to help treat and protect people from HPV-associated
diseases, cancer, and infectious diseases, today announced
that an abstract has been accepted for presentation for INO-4201 as
an Ebola booster for rVSV-ZEBOV (Ervebo) at the 33rd
European Congress of Clinical Microbiology and Infectious Diseases
(ECCMID).
"We are pleased that lead investigator Dr. Angela Huttner will have the opportunity to
share important new humoral and cellular response data at ECCMID
from our recently completed Phase 1b
trial of INO-4201 as an Ebola booster vaccine candidate for
Ervebo," said Dr. Laurent Humeau,
INOVIO's Chief Scientific Officer.
Details of the ECCMID presentation are as follows:
Title: Safety and immunogenicity of the DNA vaccine
candidate INO-4201 followed by electroporation as booster
vaccination in healthy, rVSV-ZEBOV-primed volunteers: an
investigator-initiated phase 1b,
placebo-controlled, randomized clinical trial (Boost-EBOV)
Abstract Number: MMK0202
Session: Late-breaking trial results for COVID and other
viral infections
Session Date and Time: Sunday, April 16, 8:30-10:30 am CEST
Location: Hall K
The data to be presented comes from a Phase 1b trial spearheaded by Global Urgent and
Advanced Research and Development (GuardRX), sponsored by Geneva
University Hospitals, and funded by the U.S. Defense Advanced
Research Projects Agency. Dr Huttner is an Infectious Disease
Consultant at Geneva University Hospitals.
About INO-4201
INO-4201 is a DNA vaccine targeting Zaire Ebola virus (ZEBOV)
glycoprotein (GP), designed to prevent ZEBOV infection. INO-4201
encodes for a synthetic consensus antigen that encompasses ZEBOV
genetic variability from various outbreak strains to broaden immune
coverage for divergent ZEBOV variants.
INO-4201 was evaluated in a 46-participant randomized,
placebo-controlled Phase 1b trial
(NCT04906629) to assess its safety, tolerability, and
immunogenicity in healthy adult participants who previously
received a single injection of Ervebo, a vaccine approved by the
U.S. Food and Drug Administration for the prevention of disease
caused by Zaire
ebolavirus in individuals 18 years of age and older. The
participants were dosed with 1 mg of INO-4201 injected
intradermally followed by electroporation using INOVIO's
investigational proprietary smart device,
CELLECTRA®.
About Ebola Virus Disease
The Ebola virus family includes four virus species that cause
periodic outbreaks of a highly contagious and lethal human
infectious disease – called Ebola Virus Disease (EVD). The virus is
transmitted from wild animals to people then easily spreads via
human-to-human transmission. Disturbingly, new research suggests
dormant Ebola virus in a previously infected survivor could
re-emerge up to nearly 5 years later and again allow human-to-human
transmission. Ebola virus is classified as a Category A Priority
Pathogen by the U.S. Centers for Disease Control and Prevention
(CDC). This designation indicates a national security risk, and the
U.S. FDA has an accelerated development approval pathway for
vaccines against such pathogens. Also, the World Health
Organization (WHO) continues to list Ebola Virus Disease as a
priority for research and development in emergency contexts and
coordinates planning to prevent and respond to Ebola epidemics.
About INOVIO
INOVIO is a biotechnology company focused on developing and
commercializing DNA medicines to help treat and protect people from
HPV-associated diseases, cancer, and infectious diseases. INOVIO's
DNA medicines in development are delivered using its
investigational proprietary smart device, CELLECTRA®, to
produce immune responses against targeted pathogens and cancers.
For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson (267)
429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267)
440-4298 thomas.hong@inovio.com
View original
content:https://www.prnewswire.com/news-releases/inovio-announces-acceptance-of-abstract-for-oral-presentation-on-ino-4201-as-an-ebola-booster-for-rvsv-zebov-ervebo-at-eccmid-2023-301795158.html
SOURCE INOVIO Pharmaceuticals, Inc.